Each component represents multiple points that are targetable aspects in leukemia treatment and drugs such as ruxolinib for JAK/STAT inhibition and everolimus for mammalian targeting of rapamycin (mTOR) inhibition are in clinical trials to determine their utility in pediatric ALL [78]. This evidence concerns the gene MTOR and leukemia.